PhnyX Lab
Category: AI in Healthcare
PhnyX Lab is a biopharma AI platform that transforms pharmaceutical workflows with intelligent document automation, AI-powered literature review, and regulatory writing tools. PhnyX Lab was founded in 2024. The company is led by Minseok Bae. Based in Palo Alto, USA & Seoul, South Korea. Team size: 2-10. Total funding raised: $4M. Latest round: Seed. Key investors include SK Networks, Aidan Gomez, Illia Polosukhin.
- Founded
- 2024
- Headquarters
- Palo Alto, USA & Seoul, South Korea
- Team size
- 2-10
- Total funding
- $4M
Value proposition
To enhance efficiency and productivity for professionals in the pharmaceutical and healthcare industries by simplifying research, market analysis, and automating workflows.
Products and solutions
Cheiron: A generative AI platform specialized in the medical field for tasks like literature search, data analysis, and clinical trial design.
Unique value
PhnyX Lab's uniqueness lies in its specialized focus on the biopharma industry, offering a tailored AI solution (Cheiron) as opposed to general-purpose AI models. Their platform is designed to handle the specific and complex data and workflows of the pharmaceutical sector.
Target customer
Pharmaceutical companies, life science companies, and biopharma researchers.
Industries served
Pharmaceuticals, Biotechnology, Life Sciences, Healthcare
Technology advantage
The core technological advantage is their modular Retrieval-Augmented Generation (RAG) system, which allows for high precision and speed in data retrieval and analysis. A key business advantage is the strong backing from SK Networks and prominent angel investors like Aidan Gomez and Illia Polosukhin, which provides significant industry connections and capital.
How they differentiate
PhnyX Lab differentiates itself through its core Modular RAG architecture, designed to overcome limitations of traditional Large Language Models and provide more accurate, secure, and reliable information for pharmaceutical workflows.
Main competitors
BenchSci, Genesis Therapeutics, Atomwise
Key partnerships
SK Networks (Lead Investor), SK Biosciences (Strategic MOU for AI-based drug discovery)
Notable customers
Notable customers and case studies are not yet public as the company is in early stages.
Major milestones
Closed $4 million seed funding round led by SK Networks., Launched Korea's first enterprise solution based on Modular RAG technology., Established presence in US (Palo Alto) and South Korea (Seoul).
Growth metrics
Specific growth metrics are not publicly available at this time.
Market positioning
PhnyX Lab positions itself as a pioneering generative AI startup focused on transforming operational workflows in life science companies and aims to be a leading biopharma AI platform.
Geographic focus
United States and South Korea, with offices in Palo Alto, USA, and Seoul, South Korea.
Patents and IP
Information on patents or IP is not publicly available.
About Minseok Bae
Co-Founder and CEO at PhnyX Lab. Previously, a Graduate Research Assistant at Stanford University School of Medicine.
Official website: https://www.phnyx.ai/